Mar 02, 2023 / 02:00AM GMT
Presentation
Mar 02, 2023 / 02:00AM GMT
=====================
Corporate Participants
=====================
* Patrick Nelson
ReachMarkets - MD
* Steven Yatomi-Clarke
Prescient Therapeutics Ltd - CEO and MD
=====================
Patrick Nelson - ReachMarkets - MD
All right, good afternoon and welcome to Prescient Therapeutics Investor Briefing today. This is a special briefing to run through the Personalized Cell Therapy PTX-100. I'm Patrick Nelson, MD of Reach. I'll host the session and as mentioned, we're holding this session in response to a lot of interesting inquiries that we've seen by investors on recent data release on PTX-100.
To run the session, however, we've got the MD of PTX, Steven Yatomi-Clarke. And thank you for everyone taking the time, shareholders, and new investors, for taking the time to join the session today. Prescient Therapeutics is an Australian biotech which is on a mission to take cancer treatment conversation from fight towards personalized cure.
The company has developed a diversified
Prescient Therapeutics Ltd Corporate Presentation Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot